Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails (original) (raw)
Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233–5239 ArticlePubMedCAS Google Scholar
Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:294–305 ArticlePubMedCAS Google Scholar
Gattinoni L, Klebanoff CA, Palmer DC et al (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616–1626 ArticlePubMedCAS Google Scholar
Bouneaud C, Garcia Z, Kourilsky P, Pannetier C (2005) Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 201:579–590 ArticlePubMedCAS Google Scholar
Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T Cell transfer immunotherapy. Clin Cancer Res 17:4550–4557 ArticlePubMedCAS Google Scholar
Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357 ArticlePubMedCAS Google Scholar
Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129 ArticlePubMedCAS Google Scholar
Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535–546 ArticlePubMedCAS Google Scholar
Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924 ArticlePubMed Google Scholar
Yang S, Dudley ME, Rosenberg SA, Morgan RA (2010) A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 33:648–658 ArticlePubMedCAS Google Scholar
Gattinoni L, Klebanoff CA, Restifo NP (2009) Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med 1:11 Article Google Scholar
Gattinoni L, Zhong XS, Palmer DC et al (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15:808–813 ArticlePubMedCAS Google Scholar
Hinrichs CS, Spolski R, Paulos CM et al (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111:5326–5333 ArticlePubMedCAS Google Scholar
Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101:1969–1974 ArticlePubMedCAS Google Scholar
Decaluwe H, Taillardet M, Corcuff E, Munitic I, Law HK, Rocha B, Riviere Y, Di Santo JP (2010) Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors. Proc Natl Acad Sci USA 107:9311–9316 ArticlePubMedCAS Google Scholar
Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR (2009) A distinct subset of self-renewing human memory CD8 + T cells survives cytotoxic chemotherapy. Immunity 31:834–844 ArticlePubMedCAS Google Scholar
Kaka AS, Shaffer DR, Hartmaier R, Leen AM, Lu A, Bear A, Rooney CM, Foster AE (2009) Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother 32:726–736 ArticlePubMedCAS Google Scholar
Cha E, Graham L, Manjili MH, Bear HD (2010) IL-7+IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat 122:359–369 ArticlePubMedCAS Google Scholar
Markley JC, Sadelain M (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115:3508–3519 ArticlePubMedCAS Google Scholar
Li Y, Bleakley M, Yee C (2005) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175:2261–2269 PubMedCAS Google Scholar
Albrecht J, Frey M, Teschner D, Carbol A, Theobald M, Herr W, Distler E (2011) IL-21-treated naive CD45RA+CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype. Cancer Immunol Immunother 60:235–248 ArticlePubMedCAS Google Scholar
Alves NL, Arosa FA, van Lier RA (2005) IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol 175:755–762 PubMedCAS Google Scholar
Lee JB, Lee KA, Chang J (2007) Phenotypic changes induced by IL-12 priming regulate effector and memory CD8 T cell differentiation. Int Immunol 19:1039–1048 ArticlePubMedCAS Google Scholar
van Wely CA, Beverley PC, Brett SJ, Britten CJ, Tite JP (1999) Expression of L-selectin on Th1 cells is regulated by IL-12. J Immunol 163:1214–1221 PubMed Google Scholar
Ye Z, Xu S, Moyana T, Yang J, Xiang J (2008) Defect of CD8+ memory T cells developed in absence of IL-12 priming for secondary expansion. Cell Mol Immunol 5:147–152 ArticlePubMedCAS Google Scholar
Diaz-Montero CM, El Naggar S, Al Khami A, El Naggar R, Montero AJ, Cole DJ, Salem ML (2008) Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+ CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother 57:563–572 ArticlePubMedCAS Google Scholar
Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19:751–759 ArticlePubMedCAS Google Scholar
Kerkar SP, Muranski P, Kaiser A et al (2010) Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70:6725–6734 ArticlePubMedCAS Google Scholar
Riddell SR, Greenberg PD (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189–201 ArticlePubMedCAS Google Scholar
Jones S, Peng PD, Yang S et al (2009) Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene Ther 20:630–640 ArticlePubMedCAS Google Scholar
Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177:6548–6559 PubMedCAS Google Scholar
Yang S, Cohen CJ, Peng PD et al (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15:1411–1423 ArticlePubMedCAS Google Scholar
Yang S, Rosenberg SA, Morgan RA (2008) Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J Immunother 31:830–839 ArticlePubMedCAS Google Scholar
Gattinoni L, Lugli E, Ji Y et al (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17:1290–1297 ArticlePubMedCAS Google Scholar
Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA (2011) In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother 60:739–749 ArticlePubMedCAS Google Scholar
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733 ArticlePubMedCAS Google Scholar
Kochenderfer JN, Wilson WH, Janik JE et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099–4102 ArticlePubMedCAS Google Scholar
Yang S, Dudley ME, Rosenberg SA, Morgan RA (2010) A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 33:648–658 ArticlePubMedCAS Google Scholar
Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105:241–250 ArticlePubMedCAS Google Scholar
Brenchley JM, Karandikar NJ, Betts MR et al (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101:2711–2720 ArticlePubMedCAS Google Scholar
Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, Hock H, Hochedlinger K (2009) Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 41:968–976 ArticlePubMedCAS Google Scholar
Loh YH, Hartung O, Li H et al (2010) Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7:15–19 ArticlePubMed Google Scholar
Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, Mostoslavsky G, Jaenisch R (2010) Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7:20–24 ArticlePubMedCAS Google Scholar
Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12:671–684 ArticlePubMedCAS Google Scholar